Abstract
Objectives: Cirrhosis is seen in 4-8% of patients with nonalcoholicfatty liver disease (NAFLD), and death occurs in 1-5%of them due to hepatocellular carcinoma (HCC). The aim of thisstudy was to determine the factors associated with complicationsand mortality in patients with cirrhosis secondary to non-alcoholicsteatohepatitis (NASH).Materials and Methods: The patients with cirrhosis due toNASH diagnosed between 2008 and 2018 in our clinic formedthe study population. Patients with diabetes, obesity, or insulinresistance and those with cirrhosis due to other causes wereexcluded. The patients were enrolled and followed up prospectively.Results: A total of 185 patients were included in the study.The survival was 94.6% at the 1st year and 57.0% at the 5th year.Median survival duration was 5.83 years. The rate of HCCdevelopment was 0.7% at the 1st year and 9.7% at the 5th year. Inthe multivariate Cox analysis, age (OR: 1.12, 95% CI: 1.04-1.21;P = 0.003), creatinine (OR: 24.4, 95% CI: 2.32-257.8; P= 0.008)and encephalopathy (OR: 24.49, 95% CI: 1.06-19.6; p = 0.042)were found as independent predictors of mortality. Developmentof ascites occurred in 46.9%, variceal bleeding in 21.9% andencephalopathy in 18% of patients at the 5th year.Conclusion: Patients with NASH-related cirrhosis shouldbe carefully monitored for HCC development, variceal bleeding,ascites, and encephalopathy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
